Bioequivalence of Two Formulations of Gliclazide in a Randomized Crossover Study in Healthy Caucasian Subjects Under Fasting Conditions
- 27 March 2018
- journal article
- research article
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 8 (1) , 16-21
Abstract
This study aimed to investigate the bioequivalence of 2 formulations of gliclazide modified‐release tablets 60 mg in 48 healthy Caucasian volunteers under fasting conditions. A test product, Gliclazide MR (Ranbaxy Laboratories Limited, now Sun Pharmaceutical Industries, India), was compared with a reference product, Diamicron MR (Servier, France). The study was performed under a single‐dose, 2‐treatment, 2‐period, 2‐sequence crossover design in a fasted condition with a washout period of 21 days. Blood samples were collected for 96 hours after drug administration. Drug plasma concentrations were determined by a liquid chromatography–tandem mass spectrometry method. Analysis of pharmacokinetic characteristics was based on a noncompartmental model. The logarithmically transformed data of Cmax and AUC were analyzed for 90% confidence intervals using analysis of variance. There was no significant difference in pharmacokinetic characteristics between the products, and the 90% confidence intervals were within the acceptance range of 80.00%–125.00%. The investigated products were bioequivalent under fasted conditions.Keywords
Funding Information
- Ranbaxy Laboratories Limited
- Sun Pharmaceutical Industries
This publication has 4 references indexed in Scilit:
- Effects of St John's wort andCYP2C9genotype on the pharmacokinetics and pharmacodynamics of gliclazideBritish Journal of Pharmacology, 2008
- Identification of the human cytochromes P450 catalysing the rate‐limiting pathways of gliclazide eliminationBritish Journal of Clinical Pharmacology, 2007
- Gliclazide modified release: Its place in the therapeutic ArmamentariumMetabolism, 2000
- Differential sensitivity of beta-cell and extrapancreatic K ATP channels to gliclazideDiabetologia, 1999